Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1

Interventions

Oncolytic Virotherapy 2tucatinib 1trifluridine tipiracil drug combination 1tribenoside (combination) 1tribenoside 1trastuzumab deruxtecan 1tipiracil 1sotorasib 1sintilimab 1semaglutide 1regorafenib 1polyethylene glycol 400 1penpulimab 1palbociclib 1montelukast 1encorafenib 1binimetinib 1balstilimab 1adagrasib 1Trifluridine 1Tobacco Use Cessation Devices 1Tablets 1Suppositories 1Standard of Care 1Specimen Handling 1Receptor Protein-Tyrosine Kinases 1Radiosurgery 1Polyethylene Glycols 1Pentoxifylline 1Panitumumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Colorectal Neoplasms × Cannabidiol × Clear all
NCT07167446 2025-10-22

Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy

Fox Chase Cancer Center

Phase EARLY_PHASE1 Recruiting
30 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡